The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:1556-1558 October 11, 2007 Number 15
NextNext

Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Schiffer, C. A.
-PubMed Citation
To the Editor: Schiffer (July 19 issue)1 discusses some of the adverse events associated with the use of BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia (CML). We would add hypothyroidism to the list of events presented in Table 1 of the article. Hypothyroidism has been reported in patients treated with imatinib for metastatic medullary thyroid carcinoma or gastrointestinal stromal tumors (GIST).2 An increase in levothyroxine replacement was necessary in some patients who had previously undergone a thyroidectomy. Similar effects have been reported with sunitinib malate, an oral tyrosine kinase inhibitor recently developed for the treatment of GIST and renal-cell . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.